Current progress of nanomedicine for prostate cancer diagnosis and treatment

Zhao, Jiang; Zhang, Chi; Wang, Weihao; Li, Chen; Mu, Xiaoqian; Hu, Kebang

doi:10.1016/j.biopha.2022.113714

Cited by 16 publications

(12 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arnas et al suggested that high-intensity focused ultrasound (HIFU) has a high control rate and safety in the treatment of local prostate cancer patients and should be promoted in clinical treatment (24). Jiang et al also found that nanotechnology could create good synergy with radiotherapy, chemotherapy, thermotherapy, photodynamic therapy, and gene therapy, which could increase the effectiveness of treatment and reduce drug resistance (25). With the recent advances, the treatments of prostate cancer became varied, so it was particularly important to evaluate the prognosis of prostate cancer patients.…”

Section: Discussionmentioning

confidence: 99%

C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis

Zhou

Chen

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundThe relationship between the C-reactive protein (CRP) and prognosis in prostate cancer (PCa) has been widely discussed over the past few years but remains controversial.Material and methodsIn our meta-analysis, we searched 16 reliable studies in the PubMed, Embase, and Cochrane Library databases. Otherwise, we have successfully registered on the INPLASY. We also performed random- and fixed-effects models to evaluate the hazard ratio (HR) and 95% confidence interval (CI), respectively.ResultThe result of our meta-analysis shows that elevated CRP levels were related to worse overall survival (OS) (HR = 1.752, 95% CI = 1.304–2.355, p = 0.000), cancer-specific survival (CSS) (HR = 1.663, 95% CI = 1.064–2.6, p = 0.026), and progression-free survival (PFS) (HR = 1.663, 95% CI = 1.064–2.6, p = 0.026) of PCa patients. There was significant heterogeneity, so we performed a subgroup analysis according to the staging of the disease and found the same result. Furthermore, the heterogeneity was also reduced, and no statistical significance.ConclusionOur study shows that the level of CRP could reflect the prognosis of prostate cancer patients. We find that PCa patients with high levels of CRP often have worse OS, CSS, and PFS, although the stages of the patients’ disease are different. More studies are needed to verify this idea.

show abstract

Section: Discussionmentioning

confidence: 99%

C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis

Zhou

Chen

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…The results of this study, where MCL for mHT was used, are comparable with those of previous studies [ 18 , 19 , 20 ]. The use of nanotechnology to diagnose or treat PC has attracted attention [ 34 ]. Synergy with nanotechnology and multimodal therapy including radiotherapy, chemotherapy, and gene therapy are expected [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

“…The use of nanotechnology to diagnose or treat PC has attracted attention [ 34 ]. Synergy with nanotechnology and multimodal therapy including radiotherapy, chemotherapy, and gene therapy are expected [ 34 ]. One of the advantages of coupling CNH is the potential use as a drug carrier; hence, it has a significant development potential compared with IONP alone, which can only provide hyperthermia for PC.…”

Section: Discussionmentioning

confidence: 99%

Role of HIKESHI on Hyperthermia for Castration-Resistant Prostate Cancer and Application of a Novel Magnetic Nanoparticle with Carbon Nanohorn for Magnetic Hyperthermia

et al. 2023

View full text Add to dashboard Cite

The prognosis of castration-resistant prostate cancer (CRPC) is technically scarce; therefore, a novel treatment for CRPC remains warranted. To this end, hyperthermia (HT) was investigated as an alternative therapy. In this study, the analysis focused on the association between CRPC and heat shock protein nuclear import factor “hikeshi (HIKESHI)”, a factor of heat tolerance. Silencing the HIKESHI expression of 22Rv1 cells (human CRPC cell line) treated with siRNAs inhibited the translocation of heat shock protein 70 from the cytoplasm to the nucleus under heat shock and enhanced the effect of hyperthermia. Moreover, a novel magnetic nanoparticle was developed via binding carbon nanohorn (CNH) and iron oxide nanoparticle (IONP) with 3-aminopropylsilyl (APS). Tumor-bearing model mice implanted with 22 Rv1 cells were examined to determine the effect of magnetic HT (mHT). We locally injected CNH-APS-IONP into the tumor, which was set under an alternative magnetic field and showed that tumor growth in the treatment group was significantly suppressed compared with other groups. This study suggests that HIKESHI silencing enhances the sensitivity of 22Rv1 cells to HT, and CNH-APTES-IONP deserves consideration for mHT.

show abstract

“…Since the first nano-based cancer drug (Doxil) was approved by FDA in 1995, nanomedicines have been authorized in a few kinds of cancers therapies, such as ovarian and non-small-cell lung cancer, myeloma, osteogenic sarcoma ( He et al, 2019 ; Zhao et al, 2022 ). There are a few PC nanomedicines employed in clinical phase Ⅱ, such as BIND-014, Tecemotide, and CT-2103 and clinical data shows the positive efficiency of BIND-014 ( Autio et al, 2018 ; He et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Advanced nanomaterial for prostate cancer theranostics

Hao

Li²,

Cheng³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Prostate cancer (PC) has the second highest incidence in men, according to global statistical data. The symptoms of PC in the early stage are not obvious, causing late diagnosis in most patients, which is the cause for missing the optimal treatment time. Thus, highly sensitive and precise early diagnosis methods are very important. Additionally, precise therapy regimens for good targeting and innocuous to the body are indispensable to treat cancer. This review first introduced two diagnosis methods, containing prostate-specific biomarkers detection and molecular imaging. Then, it recommended advanced therapy approaches, such as chemotherapy, gene therapy, and therapeutic nanomaterial. Afterward, we summarized the development of nanomaterial in PC, highlighting the importance of integration of diagnosis and therapy as the future direction against cancer.

show abstract

Current progress of nanomedicine for prostate cancer diagnosis and treatment

Cited by 16 publications

References 194 publications

C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis

C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis

Role of HIKESHI on Hyperthermia for Castration-Resistant Prostate Cancer and Application of a Novel Magnetic Nanoparticle with Carbon Nanohorn for Magnetic Hyperthermia

Advanced nanomaterial for prostate cancer theranostics

Contact Info

Product

Resources

About